Sanofi EPS - Earnings per Share 2010-2024 | SNY

Sanofi annual and quarterly earnings per share history from 2010 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Sanofi EPS for the quarter ending September 30, 2024 was $1.24, a 12.76% increase year-over-year.
  • Sanofi EPS for the twelve months ending September 30, 2024 was $1.96, a 49.19% decline year-over-year.
  • Sanofi 2023 annual EPS was $2.33, a 33.68% decline from 2022.
  • Sanofi 2022 annual EPS was $3.51, a 19.84% increase from 2021.
  • Sanofi 2021 annual EPS was $2.93, a 47.53% decline from 2020.
Sanofi Annual EPS
2023 $2.33
2022 $3.51
2021 $2.93
2020 $5.58
2019 $1.25
2018 $2.03
2017 $3.76
2016 $2.01
2015 $1.81
2014 $2.19
2013 $1.85
2012 $2.41
2011 $2.83
2010 $2.85
2009 $2.77
Sanofi Quarterly EPS
2024-09-30 $1.24
2024-06-30 $0.48
2024-03-31 $0.49
2023-12-31 $-0.25
2023-09-30 $1.10
2023-06-30 $0.63
2023-03-31 $0.86
2022-12-31 $1.27
2022-09-30 $0.84
2022-06-30 $0.50
2022-03-31 $0.90
2021-09-30 $1.09
2021-06-30 $0.00
2021-03-31 $0.75
2020-09-30 $0.91
2020-03-31 $0.75
2019-09-30 $0.78
2019-03-31 $0.52
2018-03-31 $0.50
2017-12-31 $0.17
2017-09-30 $0.74
2017-06-30 $0.45
2017-03-31 $2.41
2016-12-31 $0.31
2016-09-30 $0.73
2016-06-30 $0.51
2016-03-31 $0.46
2015-09-30 $0.70
2015-06-30 $0.55
2014-06-30 $0.41
2013-06-30 $0.22
2012-06-30 $0.57
2012-03-31 $0.91
2011-12-31 $0.71
2011-09-30 $1.05
2011-06-30 $0.56
2011-03-31 $1.22
2010-12-31 $0.22
2010-09-30 $0.85
2010-06-30 $0.85
2010-03-31 $1.23
2009-12-31 $0.63
2009-09-30 $1.26
2009-06-30 $1.24
2009-03-31 $1.08
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $134.378B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $765.281B 79.27
Novo Nordisk (NVO) Denmark $492.372B 37.58
Johnson & Johnson (JNJ) United States $380.982B 15.45
AbbVie (ABBV) United States $354.099B 18.65
Merck (MRK) United States $258.017B 17.12
Novartis AG (NVS) Switzerland $225.903B 15.02
AstraZeneca (AZN) United Kingdom $221.475B 19.73
Pfizer (PFE) United States $157.307B 10.76
Innoviva (INVA) United States $1.211B 6.72